Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences, Inc. reported strong financial results for Q1 2026, achieving a 13% revenue increase to $19.7 million. Interventional Glaucoma revenue grew 7% to $18.3 million, while Interventional Dry Eye revenue nearly doubled to $1.4 million. The company has raised its revenue guidance for the full year 2026 to $83.0 million to $89.0 million, reflecting a positive outlook. Gross profit for the quarter was $17.0 million with a gross margin of 86%. Operating expenses increased slightly due to a one-time legal fee but were offset by lower R&D expenditures. The net loss narrowed to $13.0 million.
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026.